Source link : https://www.newshealth.biz/health-news/for-ibd-no-cardiovascular-risk-difference-between-jak-tnf-inhibitors/
ORLANDO — Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, according to a retrospective single-center study. In a matched analysis, rates of major adverse cardiac events were 3.10% for patients taking the JAK inhibitors tofacitinib (Xeljanz) or […]
Author : News Health
Publish date : 2024-12-19 21:30:00
Copyright for syndicated content belongs to the linked Source.